ArticleThe New England journal of medicine2018
Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
Article in The New England journal of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Trial
- Oncogene-driven lung cancer in the era of radiogenomics: current evidence and future developments.Discover oncology · 2025Review
- Crosstalk between lipid metabolism and EMT: emerging mechanisms and cancer therapy.Molecular and cellular biochemistry · 2025Article
- Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study.JTO clinical and research reports · 2024Article
- The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis.Current oncology (Toronto, Ont.) · 2022Article
- An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.Nature cancer · 2022Article
- Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.Oncoimmunology · 2022Review
- Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.Annals of medicine · 2021Article
- Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials.Clinical drug investigation · 2021Article
- Neoadjuvant treatment of stage IIIA-N2 inTranslational lung cancer research · 2021Review
- Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.BMC cancer · 2020Article
- [Immunohistochemical and molecular pathological diagnosis of lung carcinoma].Der Pathologe · 2020Review
- Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.Frontiers in oncology · 2020Review
- FDA- and EMA-Approved Tyrosine Kinase Inhibitors in AdvancedBiomolecules · 2019Review
- Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.Lung cancer (Amsterdam, Netherlands) · 2018Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29590540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.